EC Number   |
Application |
Reference |
|---|
   3.4.21.B12 | medicine |
KLK4 is a proliferative factor with effects on cell cycle-related gene expression. It may have an important role in prostate cancer development and progression |
685946 |
| 3.4.21.B12 | medicine |
naturally occuring gene mutation G214A results in a truncated enzyme that lacks residue S207 of the catalytic triad. Mutation affects tooth enamel formation causing the enamel crystallites to grow incompletely in thickness or width but to normal length, i.e. autosomal recessive hypomaturation amelogenesis imperfecta |
669814 |
| 3.4.21.B12 | medicine |
no significant differences in enzyme protein content between healthy prostate tissue and malignant or benign prostate |
668285 |
| 3.4.21.B12 | medicine |
patients with epithelial ovarian carcinoma, carcinoma cells expressed enzyme in 80% of effusions and 82% of solid tumors, levels are highest in effusions. Enzyme expression does not predict survival |
667120 |
| 3.4.21.B12 | medicine |
tumor-associated overexpression of tissue kallikreins contributes to ovarian cancer progression. OV-MZ-6 ovarian cancer cells simultaneously expressing K4-7 display similar proliferative capacity as the vector-transfected control cells, but show significantly increased invasive behavior. Simultaneous expression of K4-7 in OV-MZ-6 cells and inoculated into the peritoneum of nude mice, results in a remarkable 92% mean increase in tumor burden compared to control cell line |
664273 |
